好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Relevance of Interleukin-6 in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Systematic Review with Meta-analysis
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
1-005
To summarize the current evidence on the levels of interleukin-6 (IL-6) in cerebrospinal fluid (CSF) and serum of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
IL-6 is implicated in MOGAD's pathophysiology, but data on its levels in CSF and serum, and its clinical significance, remain limited. Understanding IL-6 levels may aid in its role as a potential biomarker for MOGAD. 
A systematic search of five databases (PubMed, Embase, Scopus, Web of Science, and Google Scholar) was conducted until September 2025. Observational studies measuring IL-6 in CSF and serum of MOGAD patients were included. Meta-analysis using Standardized Mean Difference (SMD) with a random-effects model was applied to estimate pooled effects. A narrative synthesis was provided when meta-analysis was not possible. Risk of bias was assessed using the Newcastle-Ottawa scale.
Seven studies (621 patients) were included. CSF IL-6 levels were significantly elevated in MOGAD compared to controls (SMD = 2.72; 95% CI 0.15 to 5.29; I² = 95.2%). Comparisons with MS showed no significant differences in serum (MD = 0.68; 95% CI –1.18 to 2.54; I² = 87.3%), but a significant difference in CSF (SMD = 0.78; 95% CI 0.44 to 1.12; I² = 0%). Comparisons with NMOSD showed no significant differences in serum (MD = –0.58; 95% CI –1.14 to –0.01; I² = 0%) or CSF (SMD = 0.16; 95% CI –0.28 to 0.60; I² = 0%). All studies showed a low risk of bias.

IL-6 levels in CSF are elevated in MOGAD compared to controls, though high heterogeneity in studies limits generalizability. IL-6 showed significant differences in CSF between MOGAD and MS, but not with NMOSD. These findings suggest that IL-6 may not be a reliable biomarker for MOGAD, especially in serum. Further research with larger samples and standardized methodologies is needed to confirm its clinical utility.
Authors/Disclosures
Bryan E. Rudas Sulca, Medical student
PRESENTER 		Mr. Rudas Sulca has nothing to disclose.
Gerardo M. Luna-Peralta Mr. Luna-Peralta has nothing to disclose.
Alvaro J. Milla-Martinez Mr. Milla-Martinez has nothing to disclose.
Freddy F. Arcos Rivera Mr. Arcos Rivera has nothing to disclose.
Ivan Alegre-Cordero Mr. Alegre-Cordero has nothing to disclose.
Leonardo Di Cosmo, Student Mr. Di Cosmo has nothing to disclose.
Danielle Kei Pua, MD (Westchester Medical Center) Dr. Pua has nothing to disclose.